Evidence map›Paper›PMID 40542321›Full record

ArticleJournal of cancer survivorship : research and practice2025

Pattern of change and predictors of cognitive function in older adults receiving allogeneic hematopoietic cell transplantation using the Montreal cognitive assessment.

Thuy T Koll, Jillian Timperley, Moataz Ellithi, Vijaya R Bhatt, Hongying Dai, Marcia Free, Amelia L Nelson-Sheese, Patrick J Smith, Lauren Hill, Ernaya Johnson and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Thuy T KollDivision of Geriatrics, Gerontology, and Palliative Medicine, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. thuy.koll@unmc.edu.
Jillian TimperleyDivision of Geriatrics, Gerontology, and Palliative Medicine, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Moataz EllithiDivision of Hematology Oncology, Department of Internal Medicine, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Vijaya R BhattDivision of Hematology Oncology, Department of Internal Medicine, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Hongying DaiDepartment of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA.
Marcia FreeDivision of Geriatrics, Gerontology, and Palliative Medicine, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Amelia L Nelson-SheeseDivision of Neuropsychology, Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
Patrick J SmithDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
Lauren HillDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
Ernaya JohnsonDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
Rebecca A ShelbyDepartment of Psychiatry and Behavioral Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Caroline S DorfmanDepartment of Psychiatry and Behavioral Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Aaron T ZhaoDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
Tanya M WildesDivision of Hematology Oncology, Department of Internal Medicine, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Daniel L MurmanDepartment of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
Alfred L FisherDivision of Geriatrics, Gerontology, and Palliative Medicine, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Anthony D SungDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.

Funding

UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 1985 to 2026
$55.0M
Resource Core 3 - Metabolomics CoreP30AG028716 · NIA · DUKE UNIVERSITY · PI CATHLEEN S COLON-EMERIC, Susan Nicole Hastings · 2006 to 2026
$24.6M
Aging trajectories and outcomes of older adults with acute myeloid leukemiaR37CA276928 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Vijaya Raj Bhatt · 2023 to 2026
$2.1M
Promoting Physical Activity to Improve Cognitive Function in Older Adults Undergoing Hematopoietic Cell Transplantation (HCT)K23AG070311 · NIA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KOLL, THUY · 2021 to 2025
$1.1M
NCI NIH HHS P30 CA036727NCI NIH HHS R37 CA276928NIA NIH HHS K23 AG070311NIA NIH HHS K23AG070311NIA NIH HHS P30 AG028716NIA NIH HHS P30AG028716
6 · The paper itself

Abstract

purposeThis study examined the pattern of change in cognitive function using the Montreal Cognitive Assessment (MoCA) in the context of physical function and identified risk factors for poor cognitive function post allogeneic HCT in adults ≥ 60 years. MATERIALS AND

methodsThis is a two-center prospective cohort study, measuring cognitive and physical function pre-HCT and 3 months post-HCT. A MoCA score of 26 and above is considered normal. We defined mild impairment as a MoCA score of 23-25, and < 23 as moderate impairment. The Sankey plot was generated to assess the transition of impairment status on the MoCA screen from pre-HCT to 3 months post-HCT. The association of predetermined clinical and demographic variables and 3-month cognitive function and cognitive categories was determined using linear mixed-effects model and ordinal logistic regression, respectively. Predetermined variables including physical function, age, gender, education, depressive symptoms, KPS, HCT-CI, disease type, and treatment intensity were used in multivariate analyses.

resultsA total of 171 participants were identified. Pre-HCT, 84 (49%) had normal MoCA scores, 51 (30%) had mild, and 36 (21%) had moderate impairment scores. The prevalence of post-HCT mild impairment scores decreased, and moderate impairment scores nearly doubled. Female gender and pre-HCT functional mobility impairment predicted performance on the MoCA post-HCT above and beyond pre-HCT depressive symptoms, comorbid conditions, KPS, and transplant-related factors. Pre-HCT MoCA and functional mobility scores also predicted post-HCT cognitive categories (normal, mild and moderate impairment).

conclusionOur findings suggest that the pre-HCT MoCA screen can identify those at risk for cognitive impairment post-HCT and can help monitor cognitive function post-HCT. IMPLICATIONS FOR CANCER SURVIVORS: Employing the widely used MoCA threshold for impairment (MoCA < 26) could fail to identify a subgroup requiring intervention and monitoring.

Indexed as

Cognitive impairmentCognitive screensHematological malignanciesHematopoietic cell transplantMontreal Cognitive Assessment (MoCA)Older adults

Identifiers

PMID40542321
PMCPMC12257985

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.